Jean Duval

Ms. Duvall is Co-Founder and Chair of cell and gene therapy specialist, Trizell Holding, a subsidiary of Ferring Pharmaceuticals. Ms. Duvall co-initiated and drove Ferring’s entry into gene and cell therapy by leading the acquisition of assets and founding of Trizell. She has since grown the company from ~50 to 250 employees, and into a fully integrated group incl. R&D and manufacturing capabilities in Finland, UK, and Switzerland.

Ms. Duvall was previously Executive Vice President at Ferring Pharmaceuticals, where she was responsible for all legal activities on a global basis, serving also as the secretary to the board of directors. With experience in managing pharmaceuticals regulatory changes from a legal perspective, prior to joining Ferring she was general counsel at major drugs firm, Elan Corporation.

Ms. Duvall has a Bachelor of Science degree from Case Western Reserve University and a juris doctor degree from Ohio State University.